Want to see HK:2393 full AI Analyst Report?
2393 Stock Chart & Stats
HK$0.06
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.06
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.04 - HK$0.19
Previous CloseN/A
Volume70.00K
Average Volume (3M)2.34M
Market Cap
HK$135.12M
Enterprise ValueHK$117.23M
Total Cash (Recent Filing)HK$234.51M
Total Debt (Recent Filing)HK$211.05M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,331,590,000
10 Day Avg. Volume1,184,000
30 Day Avg. Volume2,342,546
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetThe company reversed prior solvency strain by restoring positive equity and materially reducing leverage (debt-to-equity ~0.56). That stronger balance sheet raises financial flexibility, lowers refinancing risk and supports investment or cyclical cushions over the next several quarters.
Strong 2025 Cash GenerationOperating and free cash flow rebounded sharply in 2025, producing meaningful internal funding (~311M OCF, ~289M FCF). This improves liquidity and ability to fund operations, maintenance capex, or deleveraging without relying solely on external financing in the medium term.
Service-platform Business ModelThe firm operates consumer-facing medical aesthetic and eye-care service platforms, which are structurally attractive: repeat visits, cross-sell of treatments/products and localized clinic networks can generate recurring revenue and scale operational margins over time.
Bears Say
Sharp Revenue ContractionA pronounced revenue decline (~25% in 2025) signals weakening demand or market share loss. Persistent top-line erosion undermines unit economics and capacity utilization, making margin recovery and sustainable growth more difficult absent structural demand improvement or strategic corrective action.
Return To Net LossesThe shift back to net losses and highly variable margins indicate unstable earnings power. This volatility constrains reinvestment, harms return on equity, and reduces predictability of future cash generation, complicating long-term planning for expansion or shareholder returns.
Cash-flow Volatility HistoricallyHistorical swings in operating and free cash flow (negative in 2022, weak in 2024) mean the 2025 rebound may not be durable. This volatility raises refinancing and investment risk during downturns and limits confidence that internal cash will reliably fund growth or debt service.
Yestar Healthcare Holdings Co Ltd News
2393 FAQ
What was Yestar Healthcare Holdings Co Ltd’s price range in the past 12 months?
Yestar Healthcare Holdings Co Ltd lowest stock price was HK$0.04 and its highest was HK$0.19 in the past 12 months.
What is Yestar Healthcare Holdings Co Ltd’s market cap?
Yestar Healthcare Holdings Co Ltd’s market cap is HK$135.12M.
When is Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date?
Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.
How were Yestar Healthcare Holdings Co Ltd’s earnings last quarter?
Yestar Healthcare Holdings Co Ltd released its earnings results on Mar 27, 2026. The company reported -HK$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.038.
Is Yestar Healthcare Holdings Co Ltd overvalued?
According to Wall Street analysts Yestar Healthcare Holdings Co Ltd’s price is currently Overvalued.
Does Yestar Healthcare Holdings Co Ltd pay dividends?
Yestar Healthcare Holdings Co Ltd pays a Annually dividend of HK$0.055 which represents an annual dividend yield of N/A. See more information on Yestar Healthcare Holdings Co Ltd dividends here
What is Yestar Healthcare Holdings Co Ltd’s EPS estimate?
Yestar Healthcare Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yestar Healthcare Holdings Co Ltd have?
Yestar Healthcare Holdings Co Ltd has 2,331,590,000 shares outstanding.
What happened to Yestar Healthcare Holdings Co Ltd’s price movement after its last earnings report?
Yestar Healthcare Holdings Co Ltd reported an EPS of -HK$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Yestar Healthcare Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:2393
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yestar Healthcare Holdings Co Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.60%
Trailing 12-Months
Company Description
Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents. The company also engages in the management of supply chain and service of freight transportation equipment, as well as development of biotechnology. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People’s Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Sisram Medical Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―